In our study, we took advantage of the dual advantages of TIL-T and CAR T and constructed TIL CAR-T cells capable of MHC molecules and co-stimulatory signal-independent activation with tumor-specific broad-spectrum TCR expression. The gene discussed is HLA-C; the disease is neoplasm.